Gelesis files for Chapter 7 liquidation, putting Plenity's US availability in doubt

On October 30, 2023, Gelesis Holdings, Inc. and its two US operating subsidiaries, Gelesis, Inc. and Gelesis, LLC, ceased operations and filed a voluntary petition for Chapter 7 liquidation in the US Bankruptcy Court for the District of Delaware, Case No. 23-11787 ^[1]. The filing came "after considering all strategic alternatives," according to the company's regulatory disclosure ^[1]. Chapter 7 is a full liquidation process, not a reorganization, which means the company as it existed did not continue ^[1].

Gelesis listed assets of $50 million to $100 million against $44.34 million in liabilities ^[2]. The company was represented in the filing by Kenneth Listwak of Troutman Pepper Hamilton Sanders LLP ^[2]. Under Chapter 7, a court-appointed trustee takes control of the company's assets and liabilities, which "effectively eliminat[es] the authority and powers of the Board of Directors" and its executives ^[1].

Concurrent with the filing, chief executive Yishai Zohar and chief operating officer David Pass resigned, and the entire board of directors — Paul Fonteyne, Alison Bauerlein, Kathryn Cavanaugh, Clayton Christopher, Jane Wildman and Zohar — also resigned ^[1]. The disclosure states that as of October 30, 2023, "the Company has no officers, consultants or employees" ^[1].

Plenity is an orally administered capsule that had been sold in the US by prescription through telehealth consultations, according to the company's own description of its business ^[2]. Gelesis described itself as a commercial-stage company developing superabsorbent hydrogel therapeutics for gastrointestinal conditions including excess weight, type 2 diabetes, fatty liver disease, constipation and inflammatory bowel disease ^[2].

Why it matters for patients

Plenity is not a GLP-1 medicine like semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound). It worked differently, as a hydrogel capsule taken with water before meals, and it had served as a lower-cost, non-injectable option for some people managing their weight. Its maker's collapse shows that having FDA clearance does not guarantee a product stays on pharmacy shelves. A company can run out of money and be forced to liquidate even after its product has cleared regulatory review. For anyone who had been using Plenity, the bankruptcy filing means the company that made it no longer has employees or a functioning board to answer questions, and supply going forward depended on what happened to its assets in the bankruptcy process ^{[1] [2]}. The sources reviewed here do not say whether Plenity has continued to be manufactured or sold since the filing, or who ultimately controls the product; that is not yet known from the available record.

What happens next

After the October 2023 filing, the bankruptcy case moved through several stages documented in court-tracking records. A motion for joint administration of the Gelesis entities was filed on January 30, 2024, and approved on February 1, 2024 ^[2]. A motion for a sale of the company's assets was filed on April 9, 2024, and bidding procedures were approved on April 19, 2024 ^[2]. A notice naming a successful bidder was filed on May 8, 2024, and the court approved the asset sale motion on May 23, 2024 ^[2]. Separately, the company's stock, trading over the counter under the symbol GLSHQ, was worth about $0.01 per share as of April 29, 2024 ^[2]. The sources here do not specify who the successful bidder was or what plans, if any, exist for Plenity going forward.